Quote:

---

2. Nobody will be placed into a death sentence by not changing trial design since it includes the current standard of care plus Leronlimab.

---

The addition of leronlimab would greatly improve the odds of survival. However, some patients with a very heavy metastatic burden may succumb that would otherwise survive with the addition of a PD-L1 inhibitor.